We recently published a list of 10 Stocks Lead Monday’s Charge Amid Market Bloodbath. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other stocks that lead Monday’s charge amid market bloodbath.

The stock market kicked off the trading week in a bloodbath, erasing last week’s gains, with all major indices posting heavy losses following President Donald Trump’s confirmation that tariffs on goods from Mexico and Canada are set to take effect on Tuesday.

The tech-heavy Nasdaq posted the biggest loss, down 2.64 percent, followed by S&P at 1.76 percent, and Dow Jones at 1.48 percent.

According to Trump, there was no room left for Mexico and Canada, and his 25-percent tariff for the two countries “will start.” He also signed an additional 10-percent tariff on goods from China.

Despite the market decline, ten companies bucked an overall pessimistic sentiment, making it to the top gainers list mainly due to bullish ratings and earnings performance, among others. In this article, we have detailed the reasons behind their gains.

To come up with Monday’s top gainers, we considered only the stocks with $2 billion in market capitalization and $5 million in daily trading volume.

A scientific researcher holding a petri dish containing a glycoengineered monoclonal antibody.

TG Therapeutics, Inc. (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) surged by 14.39 percent on Monday to close at $34.42 apiece as investors cheered news of impressive earnings performance last year.

In its latest earnings report, TG Therapeutics, Inc. (NASDAQ:TGTX) said it swung to a net income of $23.3 million in the last quarter of 2024 from a net loss of $14.4 million in the same period a year earlier while net income in full-year 2024 surged by 84.5 percent to $23.38 million from $12.67 million.

Revenues for the quarter expanded by 146 percent to $108.18 million from $43.97 million, while revenues for the full year grew 41 percent to $329 million from $233.7 million.

For this year, TG Therapeutics, Inc. (NASDAQ:TGTX) is targeting revenues to end at $540 million, with $525 million expected to be owed to its BRIUMVI treatment.

Operating expense is also expected to hit $300 million, excluding non-cash compensation.

Overall, TGTX ranks 2nd on our list of stocks that lead Monday’s charge amid market bloodbath. While we acknowledge the potential of TGTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TGTX but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.